Roth Capital Affirm Celator Pharma (CPXX) at 'Buy'; Says FLT3-ITD Patients Have a New Enemy in Vyxeos

Roth Capital affirms Celator Pharmaceuticals (Nasdaq: CPXX) at Buy with a price target of $22 following new FLT3-ITD+ data out over the weekend.

Analyst Joseph Pantginis noted the effectiveness of Vyxeos in FLT3-ITD+. The analyst offered the following commentary:

These ex vivo data provide insight into a potentially strong screening tool. Being able to test sensitivity to Vyxeos or another drug prior to treating a patient could increase the odds for efficacy as well as prevent treating patients with suboptimal or inefficacious drugs (including the cost savings). This testing could also be an important contributor to further clinical studies.

Recall the company already has multiple ISTs ongoing as well as planned company sponsored and cooperative group studies planned as well. The goal is to provide the broadest label possible for Vyxeos. We are now moving quickly to the planned NDA and MAA filings in 3Q16 and 1Q17 respectively based on the recent historic Phase III survival data.

We also reiterate our thesis that Vyxeos will supplant the decades old standard of care, 7+3. In supplanting the standard of care, we look in part to: 1) first data in decades to extend survival, 2) better tox profile, 3) more patients in remission who could advance to curative therapy and 4) Phase II data on healthcare resource utilization (HRU), all discussed below. Vyxeos is a straightforward approach with nothing new for physicians to learn since they are known drugs, so 1) should be easy to adopt and 2) easy to explain to patients (made the old stuff better).

For an analyst ratings summary and ratings history on Celator Pharmaceuticals click here. For more ratings news on Celator Pharmaceuticals click here.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• RBB Bancorp (RBB) PT Raised to $22 at Keefe, Bruyette & Woods
• Amazon.com (AMZN) PT Raised to $215 at UBS